Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neuro-Oncology
•
Pediatric Hematology/Oncology
•
Neurology
•
Child Neurology
•
Pediatric Oncology
•
Neurodevelopmental Disabilities
Would you recommend a specific workup or change in management for patients with severe, persistent deficits from methotrexate leukoencephalopathy?
Related Questions
How do you approach anti-seizure medication management when it was started by another team for a seizure-naive patient before/after craniotomy for a tumor?
What is the expected timeframe for the development of radiation myelitis and therapies that have helped with neurologic symptoms?
How do different inflammatory markers like CRP and ferritin contribute differently, if at all, to the monitoring of CART neurotoxicity?
What workup do you consider for a developmentally typical child with multiple large café au lait macules but no other signs of neurofibromatosis?
At what point should surgical intervention be considered for vestibular schwannomas or other tumors in pediatric NF2 patients?
What pharmacological management do you consider for self-injurious behavior in patients with autism spectrum disorder?
Would you recommend anticoagulation in a pediatric patient with metastases in a dural venous sinus?
Which interventions have you found effective for managing sensory sensitivities in children with autism spectrum disorder?
How has the recent FDA approval of tovorafenib impacted your treatment decisions for pediatric patients with relapsed/refractory low-grade glioma?
Based on the FIREFLY-1 data, would you consider using tovorafenib monotherapy front-line in pediatric patients who have low grade gliomas that are only amenable to subtotal resection or are unresectable?
